Importance Malignant primary brain tumors cause more than 15 000 deaths per year in the
United States. The annual incidence of primary malignant brain tumors is approximately 7 …

Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing
great interest in the neuro-oncology community. While several reports show that subsets of …

Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with
checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this …

Tumour-associated macrophages (TAMs) are crucial components of the tumour
microenvironment and play a significant role in tumour development and drug resistance by …

Neoadjuvant immune-checkpoint blockade therapy only benefits a limited fraction of patients
with glioblastoma multiforme (GBM). Thus, targeting other immunomodulators on myeloid …

Neutrophils are abundant immune cells in the circulation and frequently infiltrate tumors in
substantial numbers. However, their precise functions in different cancer types remain …

The most frequent adult-type primary CNS tumours are diffuse gliomas, but a large variety of
rarer CNS tumour types exists. The classification of these tumours is increasingly based on …

Cancer is still the leading cause of death globally. The approval of the therapeutic use of
monoclonal antibodies against immune checkpoint molecules, notably those that target the …

Immune-checkpoint inhibitors show promising effects in the treatment of multiple tumor
types. Biomarkers are biological indicators used to select patients for a systemic anticancer …

The limited efficacy of immunotherapies against glioblastoma underscores the urgency of
better understanding immunity in the central nervous system. We found that treatment with …